Through integrating drug prediction results, survival and dependency analyses, it was found that the BRD4 and PRKDC could be the optimal targets for treating ccRCC patients with the BAP1 mutations (Fig. 5A). The gene discussed is BAP1; the disease is nonpapillary renal cell carcinoma.